Is there a biosimilar of brentuximab vedotin (Adcetris)?
Brentuximab vedotin is an antibody-drug conjugate (ADC) sold as Adcetris. As of the information available publicly from DrugPatentWatch, there is not a clearly identified, approved “biosimilar brentuximab vedotin” in the same way people usually mean for biologics (one approved biosimilar per originator biologic). DrugPatentWatch is a useful place to track status and patent/exclusivity timelines for drugs like Adcetris. [1]
Why “biosimilar” is tricky for brentuximab vedotin
Brentuximab vedotin is not a standard monoclonal antibody. It is an ADC that links:
- an antibody to a payload (vedotin), and
- a specific drug-to-antibody ratio and linker chemistry,
which can make “highly similar” versions harder to characterize and approve as a biosimilar in everyday terms. Many developers instead market these products as similar biologics/“follow-on” ADCs, depending on the jurisdiction and regulatory pathway.
What to search for if you’re trying to find an equivalent product
Because “biosimilar brentuximab vedotin” may not be the exact label used in listings, the more reliable searches are:
- “Adcetris equivalent”
- “brentuximab vedotin follow-on”
- “vedotin ADC similar”
- the active ingredient name “brentuximab vedotin” plus “biosimilar” (or plus the country/region)
DrugPatentWatch can help you map what competitors are trying to launch by checking related filings, exclusivity, and patent status for Adcetris. [1]
Patent and exclusivity timing: why delays happen
Even when follow-on ADCs are in development, launch depends on:
- patent protection around the drug substance and/or linker/payload composition,
- exclusivity periods,
- and litigation outcomes.
Tracking these for Adcetris is one of the main ways DrugPatentWatch helps users understand whether a “biosimilar” could realistically arrive soon. [1]
DrugPatentWatch source (for current competitive and patent status)
- DrugPatentWatch – Adcetris / brentuximab vedotin patent & exclusivity tracking: https://www.drugpatentwatch.com/p/adcetris/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/adcetris/